Expertise in
5
conditions

John D. Grainger

Manchester, ENG, GB 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
5
conditions
Manchester, ENG, GB 

Overview

John Grainger practices practicing medicine in Manchester, United Kingdom.

Mr. Grainger is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Immune Thrombocytopenic Purpura (ITP), Purpura, Thrombocytopenia, Blood Clots, and Splenectomy.

He is actively involved in clinical research, co-authoring 50 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Manchester, ENG, United Kingdom

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) With Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)
Enrollment Status: Recruiting
Publish Date: March 27, 2026
Intervention Type: Drug
Study Drugs: Doxorubicin, Vincristine, Dexamethasone, Inotuzumab, Imatinib, 6-Tioguanine, Blinatumomab
Study Phase: Phase 3
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Phase 3, Prospective, Multi-center, Open Label Study to Investigate Safety, Immunogenicity and Hemostatic Efficacy of PEGylated Factor VIII (BAX 855) in Previously Untreated Patients (PUPs) < 6 Years With Severe Hemophilia A (FVIII < 1%)
Enrollment Status: Completed
Publish Date: July 28, 2025
Intervention Type: Biological
Study Drugs: PEG-Factor VIII, Eloctate ITI
Study Phase: Phase 3
View 1 Less Clinical Trial

50 Total Publications

Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary.
Avatrombopag for treating children and adolescents with immune thrombocytopenia: a plain language summary.
Journal: Expert review of hematology
Published: December 18, 2025

Frequently Asked Questions about John D. Grainger

Is John D. Grainger a top-rated expert for Immune Thrombocytopenic Purpura (ITP)?

MediFind is an objective health platform that identifies experts based on real-world data. John D. Grainger is classified as an Distinguished expert for Immune Thrombocytopenic Purpura (ITP), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does John D. Grainger participate in research or clinical trials?

Yes. John D. Grainger has published 50 articles and abstracts on conditions like Immune Thrombocytopenic Purpura (ITP). You can view a list of John D. Grainger's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Grainger's expertise for a condition
ConditionClose
    View All 11 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile